§Growth HormoneResearch protocol
Tesamorelin.
Growth Hormone Releasing Hormone Analog
A GHRH analog that specifically reduces visceral adipose tissue while increasing IGF-1.
Vial Size:
Research Use Only. PeptiJournal supports private research documentation and calculation support. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.
Calculated-volume support unavailable
This selected cited guide does not contain one unambiguous vial, per-event amount, cadence, and diluent set. No value was inferred from general library metadata. Review the cited table below before creating a private Research Use Only record.
Cited protocol & reconstitution guide
Source-backed reference fields by phase, including any volume fields authored in the cited guide.
Week 1
1 mg / 1000 mcg
Units / volume50 units (0.50 mL)
Weeks 2–12+
2 mg / 2000 mcg
Units / volume100 units (1.00 mL)
| Phase | Reference amount | Units / volume |
|---|---|---|
| Week 1 | 1 mg / 1000 mcg | 50 units (0.50 mL) |
| Weeks 2–12+ | 2 mg / 2000 mcg | 100 units (1.00 mL) |
Reconstitution by vial size
Calculated volume for each cited phase and vial variant. The highlighted column matches the selection above.
| Phase | 5 mg 2.5 mL water | 10 mg 3 mL water | 20 mg 3 mL water |
|---|---|---|---|
| Week 1 | 50 u 0.50 mL | 30 u 0.30 mL | 15 u 0.15 mL |
| Weeks 2–12+ | 100 u 1.00 mL | 60 u 0.60 mL | 30 u 0.30 mL |
Cited guide source: View source